Skip to content
10-Q

Quarterly Report

Inhibitor Therapeutics, Inc. INTI

0001493152-23-027740

← back to feed
Filed
Aug 11, 2023 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2023 · Aug 11, 2023 172M sh
Cash And Equivalents Q2 2023 · Jun 30, 2023 $10.1M
Cash And Equivalents Q2 2023 · Dec 31, 2022 $11.95M
Current Liabilities Q2 2023 · Jun 30, 2023 $43.86K
Current Liabilities Q2 2023 · Dec 31, 2022 $678.78K
Total Liabilities Q2 2023 · Jun 30, 2023 $3.04M
Total Liabilities Q2 2023 · Dec 31, 2022 $3.68M
Current Assets Q2 2023 · Jun 30, 2023 $10.16M
Current Assets Q2 2023 · Dec 31, 2022 $11.98M
Total Assets Q2 2023 · Jun 30, 2023 $10.16M
Total Assets Q2 2023 · Dec 31, 2022 $11.98M
Shares Diluted Q2 2023 · Jun 30, 2022 376.86M sh
Shares Diluted Q2 2023 · Jun 30, 2022 376.86M sh
Operating Cash Flow Q2 2023 · Jun 30, 2022 −$105.68K
Stockholders Equity restated Q2 2023 · Jun 30, 2022 −$3.9M
Stockholders Equity Q2 2023 · Mar 31, 2022 −$3.77M
Stockholders Equity Q2 2023 · Dec 31, 2021 −$3.62M
Eps Diluted Q2 2023 · Jun 30, 2022 $0.00
Eps Diluted Q2 2023 · Jun 30, 2022 $0.00
Eps Basic Q2 2023 · Jun 30, 2022 $0.00
Eps Basic Q2 2023 · Jun 30, 2022 $0.00
Sga Expense Q2 2023 · Jun 30, 2022 $64.65K
Sga Expense Q2 2023 · Jun 30, 2022 $158.15K
Rd Expense Q2 2023 · Jun 30, 2022 $6.15K
Rd Expense Q2 2023 · Jun 30, 2022 $6.15K
Net Income Q2 2023 · Jun 30, 2022 −$77.57K
Net Income Q2 2023 · Jun 30, 2022 −$176.48K
Net Income Q2 2023 · Mar 31, 2022 −$98.91K
Operating Income Q2 2023 · Jun 30, 2022 −$70.8K
Operating Income Q2 2023 · Jun 30, 2022 −$164.3K